The FDA Just Approved the First New Kind of ADHD Drug in Decades

Keypoints: 

• The FDA approved the first new ADHD drug class in decades.
• Simtriyo targets three brain chemicals instead of one or two.
• Four Phase 3 trials showed significant symptom improvement.
• It also improved both ADHD and anxiety in adult patients.
• One step remains, DEA scheduling before pharmacies can begin dispensing it.

Every ADHD medication available today targets one or two brain chemicals. The FDA has now approved the first treatment that works on three at once, introducing an entirely new approach instead of another variation of existing drugs.

Simtriyo (centanafadine), developed by Otsuka Pharmaceutical, won FDA approval on July 24 for patients 6 years and older who weigh at least 44 pounds. It's the first ADHD medication in a new drug class called NDSRIs, which block the reuptake of norepinephrine, dopamine, and serotonin simultaneously. No previous FDA-approved ADHD treatment has used that combination.

The decision was backed by four Phase 3 clinical trials covering children, teenagers, and adults, all showing statistically significant improvements over placebo. Otsuka also reported encouraging results in adults with both ADHD and anxiety, a combination affecting nearly half of adult ADHD patients. Participants showed measurable improvement in both conditions, with benefits beginning as early as the first week.

Experts say the approval expands treatment choices rather than replacing existing medications. Dr. Lenard Adler of NYU Langone Health, who helped lead the clinical trials, said ADHD treatment has always required individualised decisions because patients respond differently to different medicines.

One hurdle remains before patients can fill a prescription. Because Simtriyo acts on the central nervous system, it still needs a DEA scheduling decision before reaching pharmacies, a process that typically takes up to three months. How it's classified could shape how easily doctors prescribe it and how strongly it competes with medications like Adderall and Vyvanse.